Document is current
Any future updates will be listed below
-
Authors
Kosonen, Renée
Stefanoska, Kristie
Lin, Yijun https://orcid.org/0009-0006-3580-7834
Edwards, Samantha https://orcid.org/0000-0003-0991-7555
Prikas, Emmanuel https://orcid.org/0000-0001-8833-2728
Bertz, Josefine https://orcid.org/0000-0001-7030-2096
Poljak, Anne https://orcid.org/0000-0001-9953-1984
Ittner, Lars M.
Ittner, Arne https://orcid.org/0000-0001-5244-6897
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1176628)
Department of Health | National Health and Medical Research Council (2028265)
Department of Health | National Health and Medical Research Council (2029740)
Department of Health | National Health and Medical Research Council (2020624)
Department of Education and Training | Australian Research Council (DP200102396)
Department of Education and Training | Australian Research Council (DP220101900)
Department of Education and Training | Australian Research Council (DP240101654)
BrightFocus Foundation (A2022022F)
- License Information
-
More Information
Article History
Received: 6 May 2025
Accepted: 6 May 2026
First Online: 17 May 2026
Competing interests
: A.I. and L.M.I. are inventors on patents related to targeting p38γ and Thr-205 tau in Alzheimer’s and other neurological conditions (US Patent App. 17/931,229; US Patent App. 17/754,047; AU Patent 2,020,353,719) licensed to Celosia Therapeutics. L.M.I. is a shareholder of Celosia Therapeutics. The remaining authors declare no competing interests.
